The FDA has signed off on a Phase 2 clinical trial evaluating intranasal administration of Biohaven Pharmaceutical Holding Company’s (NYSE:BHVN)
migraine med vazegepant, a calcitonin gene-related peptide (CGRP)
receptor antagonist, in COVID-19 patients with pulmonary complications
who need supplemental oxygen. Shares up 4% premarket.
The rationale is that the drug may mitigate hyperimmune reactions that could prove fatal in these patients.
https://seekingalpha.com/news/3559624-biohaven-on-go-study-of-vazegepant-in-covidminus-19-others-take-action-amid-pandemic
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.